P. Chène

发表

Oligomerization of p53 upon cooperative DNA binding: towards a structural understanding of p53 function.

W. Jahnke, P. Chène, 2002, Angewandte Chemie.

The role of tetramerization in p53 function

P. Chène, Patrick Chène, 2001, Oncogene.

Functional analyses of a unique p53 germline mutant (y236Δ) associated with a familial brain tumor syndrome

M. Hegi, T. Soussi, P. Chène, 1999, International journal of cancer.

In vitro analysis of the dominant negative effect of p53 mutants.

P. Chène, 1998, Journal of molecular biology.

Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties.

P. Chène, E. Bechter, P Chène, 1999, Journal of molecular biology.

In vitro structure-function analysis of the beta-strand 326-333 of human p53.

M. Grütter, P. Mittl, P. Chène, 1997, Journal of molecular biology.

Molecular characterization of the hdm2-p53 interaction.

S F Howard, D. Lane, C. García-echeverría, 1997, Journal of molecular biology.

Influence of the N-terminal region on the oligomerisation between human and Xenopus laevis p53.

P. Chène, 1999, Journal of molecular biology.

Structure of the Dengue Virus Helicase/Nucleoside Triphosphatase Catalytic Domain at a Resolution of 2.4 Å

Subhash G. Vasudevan, Max Nanao, Ting Xu, 2005, Journal of Virology.

Drugs Targeting Protein–Protein Interactions

P. Chène, Patrick Chène, 2006, ChemMedChem.

Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.

X. Barril, B. Davis, M. Drysdale, 2009, Journal of Medicinal Chemistry.

Drugs Targeting Protein–Protein Interactions

P. Chène, 2006, ChemMedChem.

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

W. Sellers, D. Fabbro, Christopher J. Wilson, 2011, Molecular Cancer Therapeutics.

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014, Molecular Cancer Therapeutics.

Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

P. Chène, 2003, Nature Reviews Cancer.

Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Joseph Schoepfer, Joerg Kallen, Pascal Furet, 2019, ChemMedChem.

Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

P. Furet, C. García-echeverría, P. Chène, 2000, Journal of medicinal chemistry.

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.

P. Furet, A. de Pover, P. Chène, 2012, Bioorganic & Medicinal Chemistry Letters.

Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.

P. Chène, Patrick Chène, 2004, Molecular cancer research : MCR.

A critical assessment of the synthesis and biological activity of p53/human double minute 2‐stapled peptide inhibitors

T. Vorherr, P. Chène, S. Ruetz, 2017, British Journal of Pharmacology.

Towards the design of flavivirus helicase/NTPase inhibitors: crystallographic and mutagenesis studies of the dengue virus NS3 helicase catalytic domain.

P. Chène, Ting Xu, A. Sampath, 2006, Novartis Foundation symposium.

Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800

J. Brueggen, M. Drysdale, M. Jensen, 2010, Molecular Cancer Therapeutics.

Molecular Cancer Therapeutics Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP 800

J. Brueggen, M. Drysdale, M. Jensen, 2010 .

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Daniela Gabriel, Doriano Fabbro, Pascal Furet, 2008, Molecular Cancer Therapeutics.

p53 mutants without a functional tetramerisation domain are not oncogenic.

P. Chène, E. Bechter, Patrick Chène, 1999, Journal of molecular biology.

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

D. Erdmann, J. Brueggen, P. Furet, 2010, Molecular Cancer Therapeutics.

Targeting p53 in cancer.

P. Chène, 2001, Current medicinal chemistry. Anti-cancer agents.

The Effect of Hypoxia on the Expression of 150 kDa Oxygen-regulated Protein (ORP 150) in HeLa Cells

P. Chène, E. Bańkowski, M. Cechowska-Pasko, 2006, Cellular Physiology and Biochemistry.

Glucose effect on the expression of 150 kDa oxygen-regulated protein in HeLa cells.

P. Chène, E. Bańkowski, M. Cechowska-Pasko, 2005, Biochemical and Biophysical Research Communications - BBRC.

Development and Implementation of a Highly Miniaturized Confocal 2D-FIDA–Based High-Throughput Screening Assay to Search for Active Site Modulators of the Human Heat Shock Protein 90β

Alain Schilb, P. Chène, J. Schoepfer, 2004, Journal of biomolecular screening.

Mutation of asparagine 111 of rubisco from Rhodospirillum rubrum alters the carboxylase/oxygenase specificity.

A. Fersht, P. Chène, A. G. Day, 1992, Journal of molecular biology.

Role of phenylalanine-327 in the closure of loop 6 of ribulosebisphosphate carboxylase/oxygenase from Rhodospirillum rubrum.

A. Fersht, P. Chène, A. G. Day, 1993, Biochemistry.

Role of isoleucine-164 at the active site of rubisco from Rhodospirillum rubrum.

A. Fersht, P. Chène, A. G. Day, 1997, Biochemical and biophysical research communications.

Effect of the acylation of TEAD4 on its interaction with co‐activators YAP and TAZ

D. Erdmann, P. Chène, T. Schmelzle, 2017, Protein science : a publication of the Protein Society.

Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface.

D. Erdmann, P. Furet, P. Chène, 2018 .

Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface

D. Erdmann, P. Furet, P. Chène, 2018, Protein science : a publication of the Protein Society.

The Surprising Features of the TEAD4‐Vgll1 Protein–Protein Interaction

D. Erdmann, P. Chène, T. Schmelzle, 2014, Chembiochem : a European journal of chemical biology.

p53 as a drug target in cancer therapy

P. Chène, 2001 .

Study of the cytotoxic effect of a peptidic inhibitor of the p53–hdm2 interaction in tumor cells

P. Furet, P. Chène, I. Carena, 2002, FEBS letters.

Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

M. P. Dillon, R. Grotzfeld, Edward G. Lorenzana, 2019, ACS medicinal chemistry letters.

Different Recognition of TEAD Transcription Factor by the Conserved B‐strand:loop:a–helix Motif of the TEAD Binding Site of YAP and VGLL1

D. Erdmann, P. Chène, T. Schmelzle, 2016 .

Signaling Profile and Anti-Tumor Activity of the Novel HSP90 Inhibitor NVP-AUY922 in Multiple Myeloma.

H. Einsele, M. Jensen, C. García-echeverría, 2007 .

On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2

C. García-echeverría, P. Chène, G. Fendrich, 1997 .

A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors

D. Erdmann, T. Vorherr, P. Furet, 2020, Scientific Reports.

[Gastric diverticula].

P. Chène, P. Périgord, A. Simon, 1951, Gazette medicale de France.

Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system.

D. Erdmann, A. de Pover, P. Chène, 2010, Journal of biomolecular techniques : JBT.

Semiquantitative comparison of the DNA-binding activity of in vitro-synthesized proteins.

P. Chène, 1997, BioTechniques.

Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.

P. Furet, C. García-echeverría, P. Chène, 1997, Biochemistry.

Mutation of threonine-53 alters the kinetic properties of rubisco from Rhodospirillum rubrum

P. Chène, C. Chène, 1998 .

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Joerg Kallen, Pascal Furet, Keiichi Masuya, 2015, Journal of medicinal chemistry.

Identification of novel mdm2 binding peptides by phage display.

D. Lane, C. García-echeverría, P. Chène, 1996, Oncogene.

Aib-based peptide backbone as scaffolds for helical peptide mimics.

Siddhartha Roy, P. Chène, G. Basu, 2002, The journal of peptide research : official journal of the American Peptide Society.

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

H. Einsele, M. Jensen, C. García-echeverría, 2008, Leukemia.

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Joseph Schoepfer, Michael Rugaard Jensen, Robert Cozens, 2008, Breast Cancer Research.

The ATPases: a new family for a family-based drug design approach

P. Chène, 2003, Expert opinion on therapeutic targets.

Identification and characterization of NVP-BKM 120 , an orally available pan class I PI 3-Kinase inhibitor

W. Sellers, D. Fabbro, R. Schlegel, 2011 .

p53 transdominance but no gain of function in mouse brain tumor model.

A. Aguzzi, M. Hegi, P. Chène, 2000, Cancer research.

p 53 Transdominance But No Gain of Function in Mouse Brain Tumor Model 1

A. Aguzzi, M. Hegi, P. Chène, 2000 .

Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction.

P. Furet, C. García-echeverría, P. Chène, 2001, Bioorganic & medicinal chemistry letters.

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

D. Fabbro, P. Furet, C. García-echeverría, 2000, Journal of molecular biology.

INHIBITING THE p 53 – MDM 2 INTERACTION : AN IMPORTANT TARGET FOR CANCER THERAPY

P. Chène, 2022 .

PcrA/UvrD/Rep DNA helicases in bacterial genomes

P. Chène, 2008 .

Study of the ATP-binding site of helicase IV from Escherichia coli.

P. Chène, S. Dubaele, Claude Lourdel, 2006, Biochemical and biophysical research communications.

Inhibition of DNA helicases with DNA-competitive inhibitors.

P. Chène, J. Schoepfer, J. Fuchs, 2006, Bioorganic & Medicinal Chemistry Letters.

ATPases as drug targets: learning from their structure

P. Chène, Patrick Chène, 2002, Nature Reviews Drug Discovery.

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

First isolation of Yersinia ruckeri from sturgeon, Acipenser baeri Brandt, in South West of France.

P. Chène, R. Brun, R. Lesel, 1987 .

Factors influencing the inhibition of protein kinases

D. Erdmann, A. de Pover, P. Chène, 2012, Journal of enzyme inhibition and medicinal chemistry.

Kinetic Study of Human Full-Length Wild-Type JAK2 and V617F Mutant Proteins

D. Erdmann, F. Hofmann, P. Chène, 2009 .

Biochemical study of recombinant PcrA from Staphylococcus aureus for the development of screening assays.

P. Chène, J. Bohn, C. Martin, 2007, Journal of biochemistry and molecular biology.

Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases.

P. Chène, 2008, Drug discovery today.

A new perspective on the evolution of the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors

D. Erdmann, T. Vorherr, P. Furet, 2020, bioRxiv.

Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain

P. Chène, C. Rollenhagen, Christiane Rollenhagen, 1998, International journal of cancer.

Figures and figure supplements Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor

D. Erdmann, P. Chène, T. Schmelzle, 2017 .

The TEAD4–YAP/TAZ Protein–Protein Interaction: Expected Similarities and Unexpected Differences

D. Erdmann, P. Furet, F. Hofmann, 2013, Chembiochem : a European journal of chemical biology.

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

Joseph Schoepfer, Pascal Furet, R. Schmitz, 2009, BMC Chemical Biology.

Study of the Selectivity of Insulin-Like Growth Factor-1 Receptor (IGF1R) Inhibitors

D. Erdmann, P. Chène, J. Bohn, 2014 .

Microtubule assembly protects the region 28-38 of the β-tubulin subunit

P. Chène, H. Mazarguil, M. Wright, 1992 .

Phylogenetic implications of the structure-function relationships of tubulin

P. Chène, P. Rougé, H. Mazarguil, 1992 .

Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy

D. Erdmann, P. Furet, P. Chène, 2019, The FEBS journal.

Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template.

M. Grütter, P. Mittl, P. Chène, 1998, Acta crystallographica. Section D, Biological crystallography.

Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain.

C. Dekker, P. Chène, M. Eck, 2019, ACS Chemical Biology.

[Simultaneous intra- and extra- uterine pregnancies (author's transl)].

P. Chène, S. Friedman, J. Choukroun, 1981, Journal de gynecologie, obstetrique et biologie de la reproduction.

Can biochemistry drive drug discovery beyond simple potency measurements?

P. Chène, 2012, Drug discovery today.

Leveraging the Contribution of Thermodynamics in Drug Discovery with the Help of Fluorescence-Based Thermal Shift Assays

D. Erdmann, A. de Pover, P. Chène, 2011, Journal of biomolecular screening.

Design and Biochemical Characterization of Peptidic Inhibitors of the Myb/p300 Interaction.

T. Vorherr, N. Ostermann, P. Ertl, 2023, Biochemistry.

M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth

W. Sellers, S. Ferretti, F. Hofmann, 2012, Proceedings of the National Academy of Sciences.

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.

Philipp Holzer, P. Furet, P. Chène, 2016, Bioorganic & medicinal chemistry letters.

Long-range structural preformation in yes-associated protein precedes encounter complex formation with TEAD

R. Konrat, P. Chène, F. Bokhovchuk, 2022, iScience.

Study of the Digitalis genus 5 : the species Digitalis lutea

P. Chène, M. Bourge, R. Verlaque, 2016 .

The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers.

P. Chène, Annemieke Atema, 2002, Cancer letters.

Study of the TEAD‐binding domain of the YAP protein from animal species

D. Erdmann, P. Chène, F. Bokhovchuk, 2020, Protein science : a publication of the Protein Society.

An early association between the α-helix of the TEAD binding domain of YAP and TEAD drives the formation of the YAP:TEAD complex.

D. Erdmann, P. Jemth, P. Chène, 2020, Biochemistry.

Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I.

P. Furet, P. Chène, J. Schoepfer, 2009, Bioorganic & medicinal chemistry letters.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Eric Vangrevelinghe, Marc Lang, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

CANCER DE L'ESTOMAC.

P. Chène, 1963 .

Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents.

N. Munshi, D. McMillin, Jake E. Delmore, 2007 .

The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition

P. Furet, P. Chène, T. Schmelzle, 2022, ChemMedChem.

1H, 13C, 15N resonance assignment of human YAP 50–171 fragment

R. Konrat, P. Chène, F. Bokhovchuk, 2018, Biomolecular NMR assignments.

Inhibition of the p53-hdm2 Interaction with Low Molecular Weight Compounds

P. Chène, 2004, Cell cycle.

The role of lysine palmitoylation/myristoylation in the function of the TEAD transcription factors

D. Erdmann, M. Affolter, P. Chène, 2022, Scientific Reports.

Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations

P. Furet, F. Hofmann, Laurent Sansregret, 2023, Cancer Research.

Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors

P. Furet, P. Chène, T. Schmelzle, 2023, ChemMedChem.

Biochemical and Structural Characterization of a Peptidic Inhibitor of the YAP:TEAD Interaction That Binds to the α-Helix Pocket on TEAD.

P. Chène, Hanspeter Gubler, F. Villard, 2023, ACS chemical biology.

Biochemical properties of VGLL4 from Homo sapiens and Tgi from Drosophila melanogaster and possible biological implications

D. Erdmann, P. Chène, Yannick Mesrouze, 2021, Protein science : a publication of the Protein Society.

Development and implementation of a highly miniaturized confocal 2D-FIDA-based high-throughput screening assay to search for active site modulators of the human heat shock protein 90beta.

Alain Schilb, P. Chène, J. Schoepfer, 2004, Journal of biomolecular screening.

Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.

P. Furet, P. Chène, T. Schmelzle, 2019, Bioorganic & medicinal chemistry letters.

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.

E. Jacoby, Philipp Holzer, P. Furet, 2015, Bioorganic & medicinal chemistry letters.

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

J. Brueggen, M. Drysdale, R. Cozens, 2008, Breast Cancer Research.

Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors

D. Erdmann, P. Furet, P. Chène, 2019, Protein science : a publication of the Protein Society.

Author response: Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD

D. Erdmann, P. Chène, Typhaine Martin, 2017 .

Mutations at position 277 modify the DNA-binding specificity of human p53 in vitro.

P. Chène, 1999, Biochemical and biophysical research communications.

Oligomerization of p53 upon Cooperative DNA Binding: Towards a Structural Understanding of p53 Function

W. Jahnke, P. Chène, 2002 .

Inhibition of DNA Helicases with DNA‐Competitive Inhibitors.

W. Jahnke, P. Chène, J. Schoepfer, 2006 .

Fragment docking supported by NMR shift perturbations

B. Davis, M. Drysdale, M. Jensen, 2014 .

Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Philipp Holzer, P. Furet, P. Chène, 2019, ChemMedChem.

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.

P. Furet, A. de Pover, P. Chène, 2012, Bioorganic & medicinal chemistry letters.

TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.05A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA

D. Erdmann, P. Furet, P. Chène, 2018 .